Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: Breaking the link between antithrombotic potency and bleeding?

Blood

Volumn 121, Issue 16, 2013, Pages 3067-3075

  Hohmann, Jan David ^a   Wang, Xiaowei ^a,b   Krajewski, Stefanie ^a,c   Selan, Carly ^d   Haller, Carolyn A ^e   Straub, Andreas ^a,c   Chaikof, Elliot L ^e   Nandurkar, Harshal H ^d   Hagemeyer, Christoph E ^a,b   Peter, Karlheinz ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; CD39 ANTIGEN; FIBRINOGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; APYRASE; FIBRINOLYTIC AGENT; HYBRID PROTEIN; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD SAMPLING; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INTRAVITAL MICROSCOPY; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; THROMBOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; THROMBOCYTE; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ANIMALS; ANTIGENS, CD; APYRASE; BLOOD PLATELETS; DRUG DELIVERY SYSTEMS; FIBRINOLYTIC AGENTS; HUMANS; MALE; MICE; MICE, INBRED C57BL; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; THROMBOSIS;

MLCS; MLOWN;

EID: 84879139563     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-449694     Document Type: Article

References (49)

1. Brass LF, Wannemacher KM, Ma P, et al. Regulating thrombus growth and stability to achieve an optimal response to injury. J Thromb Haemost. 2011;9(suppl 1):66-75.
2. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32(23):2922-2932.
3. Rivera J, Lozano ML, Navarro-Núñez L, et al. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica. 2009;94(5): 700-711.
4. Singh M, Adigopula S, Ahmad N, et al. P2Y12 receptor antagonists in acute coronary syndrome: Clinical implications of pharmacologic and pharmacogenetic differences. Recent Patents Cardiovasc Drug Discov. 2011;6(3):207-214.
5. Damman P, Woudstra P, Kuijt WJ, et al. P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis. 2012;33(2):143-153.
6. Cattaneo M. Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thromb Haemost. 2011;105(suppl 1):S67-S74.
7. Knowles AF. The GDA1-CD39 superfamily: NTPDases with diverse functions. Purinergic Signal. 2011;7(1):21-45.
8. Enjyoji K, Sévigny J, Lin Y, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 1999;5(9): 1010-1017.
9. Hatakeyama K, Hao H, Imamura T, et al. Relation of CD39 to plaque instability and thrombus formation in directional atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol. 2005;95(5):632-635.
10. Pinsky DJ, Broekman MJ, Peschon JJ, et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest. 2002;109(8):1031-1040.
11. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest. 1997;99(6):1351-1360.
12. Marcus AJ, Broekman MJ, Drosopoulos JHF, et al. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ectonucleotidase-1: Implications for ischemic vascular diseases. J Pharmacol Exp Ther. 2003;305(1): 9-16.
13. Buergler JM, Maliszewski CR, Broekman MJ, et al. Effects of solCD39, a novel inhibitor of platelet aggregation, on platelet deposition and aggregation after PTCA in a porcine model. J Thromb Thrombolysis. 2005;19(2):115-122.
14. Marcus AJ, Broekman MJ, Drosopoulos JHF, et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost. 2005; 31(2):234-246.
15. Cai M, Huttinger ZM, He H, et al. Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury. J Mol Cell Cardiol. 2011;51(6):927-935.
16. Wheeler DG, Joseph ME, Mahamud SD, et al. Transgenic swine: Expression of human CD39 protects against myocardial injury. J Mol Cell Cardiol. 2012;52(5):958-961.
17. Crikis S, Lu B, Murray-Segal LM, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant. 2010;10(12):2586-2595.
18. Guckelberger O, Sun XF, Sévigny J, et al. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost. 2004;91(3):576-586.
19. Huttinger ZM, Milks MW, Nickoli MS, et al. Ectonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice. Am J Pathol. 2012;181(1):322-333.
20. Haller CA, Cui W, Wen J, et al. Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties. J Vasc Surg. 2006;43(4):816-823.
21. Dwyer KM, Robson SC, Nandurkar HH, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest. 2004;113(10):1440-1446.
22. Théâtre E, Frederix K, Guilmain W, et al. Overexpression of CD39 in mouse airways promotes bacteria-induced inflammation. J Immunol. 2012;189(4):1966-1974.
23. Banz Y, Beldi G, Wu Y, et al. CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. Br J Haematol. 2008; 142(4):627-637.
24. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004;92(3): 459-466.
25. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197(11):1585-1598.
26. Bellido-Martín L, Chen V, Jasuja R, et al. Imaging fibrin formation and platelet and endothelial cell activation in vivo. Thromb Haemost. 2011;105(5): 776-782.
27. Atkinson B, Dwyer K, Enjyoji K, et al. Ectonucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. Blood Cells Mol Dis. 2006;36(2):217-222.
28. Topcic D, Kim W, Holien JK, et al. An activationspecific platelet inhibitor that can be turned on/off by medically used hypothermia. Arterioscler Thromb Vasc Biol. 2011;31(9):2015-2023.
29. Straub A, Krajewski S, Hohmann JD, et al. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target. Arterioscler Thromb Vasc Biol. 2011;31(7):1607-1616.
30. Stoll P, Bassler N, Hagemeyer CE, et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol. 2007;27(5):1206-1212.
31. Schwarz M, Röttgen P, Takada Y, et al. Singlechain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J. 2004;18(14):1704-1706.
32. Kaczmarek E, Koziak K, Sévigny J, et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem. 1996;271(51):33116-33122.
33. Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med. 2009;15(6):665-673.
34. Fung CYE, Marcus AJ, Broekman MJ, et al. P2X(1) receptor inhibition and soluble CD39 administration as novel approaches to widen the cardiovascular therapeutic window. Trends Cardiovasc Med. 2009;19(1):1-5.
35. Schwarz M, Meade G, Stoll P, et al. Conformation-specific blockade of the integrin GPIIb/IIIa: A novel antiplatelet strategy that selectively targets activated platelets. Circ Res. 2006;99(1):25-33.
36. Wang X, Hagemeyer CE, Hohmann JD, et al. Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: Validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice. Circulation. 2012;125(25): 3117-3126.
37. Ta HT, Prabhu S, Leitner E, et al. Enzymatic single-chain antibody tagging: A universal approach to targeted molecular imaging and cell homing in cardiovascular disease. Circ Res. 2011; 109(4):365-373.
38. Peter K, Graeber J, Kipriyanov S, et al. Construction and functional evaluation of a singlechain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation. 2000;101(10):1158-1164.
39. von zur Muhlen C, von Elverfeldt D, Moeller JA, et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008;118(3):258-267.
40. Peter K, Gupta A, Nordt T, et al. Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner. J Cardiovasc Pharmacol. 2003;42(2):237-244.
41. Hagemeyer CE, Tomic I, Weirich U, et al. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and lowmolecular-weight urokinase. J Thromb Haemost. 2004;2(5):797-803.
42. Smith KA, Nelson PN, Warren P, et al. Demystified.recombinant antibodies. J Clin Pathol. 2004;57(9):912-917.
43. Hagemeyer CE, von Zur Muhlen C, von Elverfeldt D, et al. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost. 2009;101(6):1012-1019.
44. Robson SC, Wu Y, Sun X, et al. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost. 2005; 31(2):217-233.
45. Bönner F, Borg N, Burghoff S, et al. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PLoS ONE. 2012;7(4):e34730.
46. Rajakumar SV, Lu B, Crikis S, et al. Deficiency or inhibition of CD73 protects in mild kidney ischemia-reperfusion injury. Transplantation. 2010;90(12):1260-1264.
47. May AE, Seizer P, Gawaz M. Platelets: Inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol. 2008;28(3):s5-s10.
48. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378-3384.
49. Flögel U, Burghoff S. van Lent Plem, et al. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci Transl Med. 2012;4(146): 146ra108.